These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 549007)

  • 1. Propranolol and uraemic osteodystrophy.
    Brancaccio D; Galmozzi C; Casati S; Rurale D; Belloli S; Aroldi A; Graziani G; Ponticelli C
    Proc Eur Dial Transplant Assoc; 1979; 16():668-71. PubMed ID: 549007
    [No Abstract]   [Full Text] [Related]  

  • 2. Propranolol in uraemic osteodystrophy.
    Brancaccio D; Galmozzi C; Casati S; Ponticelli C
    Lancet; 1978 Oct; 2(8096):940. PubMed ID: 81949
    [No Abstract]   [Full Text] [Related]  

  • 3. Is calcitonin a helper of phosphate binders in the control of renal osteodystrophy?
    Ionova D; Zlatarska S; Kirjakov Z
    Nephrol Dial Transplant; 1995; 10(9):1782. PubMed ID: 8559512
    [No Abstract]   [Full Text] [Related]  

  • 4. Propranolol in uraemic osteodystrophy.
    Eastwood JB
    Lancet; 1979 Feb; 1(8112):386-7. PubMed ID: 85038
    [No Abstract]   [Full Text] [Related]  

  • 5. Dihydrotachysterol treatment in renal osteodystrophy; the effect on alkaline and acid phosphatase.
    Van Kesteren RG; Duursma SA; Dorhout Mees EJ
    Neth J Med; 1978; 21(1):17-22. PubMed ID: 634412
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term treatment of uraemic osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Nielsen SP; Binderup E; Godtfredsen WO; Jensen H; Ladefoged J
    Proc Eur Dial Transplant Assoc; 1976; 12():221-6. PubMed ID: 935114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial of calcitonin therapy in renal osteodystrophy.
    Delano BG; Baker R; Gardner B; Wallach S
    Nephron; 1973; 11(5):287-93. PubMed ID: 4753519
    [No Abstract]   [Full Text] [Related]  

  • 8. Parathyroid suppressibility in renal osteodystrophy.
    Moorhead JF; Varghese Z; Tatler GL; Baillod RA; Ku G; Sweatman AJ; Wills MR
    Proc Eur Dial Transplant Assoc; 1975; 11():465-72. PubMed ID: 1197271
    [No Abstract]   [Full Text] [Related]  

  • 9. A study of the effects of ipriflavone administration on hemodialysis patients with renal osteodystrophy: preliminary report.
    Hyodo T; Ono K; Koumi T; Miyagawa I; Okano T; Kagawa T; Hagino H; Kishimoto H; Oyama Y; Inoue A
    Nephron; 1991; 58(1):114-5. PubMed ID: 1857468
    [No Abstract]   [Full Text] [Related]  

  • 10. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
    Chantraine JM; Davin JC; Lambrechts L; Heynen G
    Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of propranolol and metoprolol on parathyroid hormone and calcitonin secretions in uraemic patients.
    Coevoet B; Desplan C; Sebert JL; Makdassi R; Andrejak M; Gheerbrant JD; Tolani M; Calmette C; Moukhtar MS; Fournier A
    Br Med J; 1980 Jun; 280(6228):1344-6. PubMed ID: 7388535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
    Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M
    Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma hydroxyproline in renal osteodystrophy.
    Varghese Z; Moorhead JF; Tatler GL; Baillod RA; Wills MR
    Proc Eur Dial Transplant Assoc; 1973; 10(0):187-96. PubMed ID: 4802560
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum hydroxyproline and renal osteodystrophy in patients maintained on haemodialysis.
    Goulding A; McChesney R; Irvine RO; Dixon SR
    N Z Med J; 1974 Dec; 80(530):540-4. PubMed ID: 4615274
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute effects of propranolol and metoprolol on plasma concentrations of parathyroid hormone and calcitonin in uraemic patients.
    Coevoet B; Desplan C; Sebert JL; Makdassi R; Gherbrand JD; Tolani M; Calmette C; Moukhtar MS; Fournier A
    Proc Eur Dial Transplant Assoc; 1979; 16():649-55. PubMed ID: 44916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plasma hydroxyproline in chronic renal failure (author's transl)].
    Heidbreder E; Lüke F; Heidland A
    Med Klin; 1976 Nov; 71(45):1945-51. PubMed ID: 995035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma hydroxyproline in uremia: relationships with histologic and biological indices of bone turnover.
    Cundy T; Bartlett M; Bishop M; Earnshaw M; Smith R; Kanis JA
    Metab Bone Dis Relat Res; 1983; 4(5):297-303. PubMed ID: 6621355
    [No Abstract]   [Full Text] [Related]  

  • 18. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
    Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of uremic osteopathy].
    Schaefer K
    Dtsch Med Wochenschr; 1980 Nov; 105(48):1670-1. PubMed ID: 7439052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.